Document Type
Article
Publication Date
2001
ISSN
0098-8588
Publisher
SAGE Publishing
Language
en-US
Abstract
Clinical trials, in which new biotech and other medical products are tested on human subjects, provide much of the data used by the FDA to determine whether the products are suitable for routine use in health care. Thus, the trials are of obvious importance to medical progress and improvement of public health, and to those who have career and financial interests at stake. But clinical trials are also important to the human subjects involved because the products being tested on them may remedy their illnesses, but may also pose risks since the products have usually not been previously tested on humans. Baram discusses the need to make clinical trials safer for human subjects.
Recommended Citation
Michael S. Baram,
Making Clinical Trials Safer for Human Subjects
,
in
27
American Journal of Law & Medicine
253
(2001).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/1739
Included in
Food and Drug Law Commons, Health Law and Policy Commons, Legal Ethics and Professional Responsibility Commons
